Food Allergies
Conditions
Keywords
Vegetable food allergy, Allergy desensitization, Lipid Transfer Proteins
Brief summary
In relation to the prognosis of vegetable FA (VFA), in contrast to other food allergies (FA), which disappear naturally with time, VFA tends to persist into adulthood and to the appearance of new sensitizations to other vegetables. The paradigm of early intervention in patients with risk factors for developing FA has changed in recent years, with evidence that maintaining a controlled diet with foods with potential allergic risk in a population of children at risk has shown efficacy in early intervention. An important aspect would be the selection of the dose of the food to be included in the diet. In this sense, recent studies on the standardization of the double-blind placebo-controlled oral challenge test (DBPCFC) in allergic patients to Lipid Transfer Proteins (LTP) with known amounts of Pru p 3 (peach LTP), have observed that the maximum tolerated dose (MTD) was equivalent to 40 grams of peach with skin. Based on these results and those obtained in the pediatric population, this study aims to evaluate whether the maintenance in the diet of a DMT evaluated in a DBPCFC could influence tolerance (desensitization) to the food at both clinical and immunological levels.
Interventions
PROCEDUREDouble-blind placebo-controlled oral challenge test (DBPCFC)
Group 1. To evaluate MTD, DBPCFC will be done with peach with skin and/or peach juice as described. The patient will remain under observation for at least 2 hours.
OTHERDietary intervention
Group 2. Patients will take for one year, MTD of fresh peach or peach juice with a frequency of 3 times/week.
Sponsors
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Women and men * 14-65 years-old * Peach allergy due to sensitization to LTP confirmed by skin tests and/or IgEe positive to Pru p 3. * Sign informed consent.
Exclusion criteria
* Pregnant of lactating women. * Patients with immunological diseases, mental illness or severe atopic dermatitis. * Patients treated with immunomodulators and/or β-blockers * Patients with forced expiratory volume (FEV1)\<70%.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the distribution of immune cell populations after MTD exposure | 1 year | Study of the clinical and immunological implications of maintaining in the diet the maximum tolerated dose identified in a controlled food exposure test according to the sensitization profile to LTPs (Real-time pilot study). |
Countries
Spain
Contacts
Primary ContactCristobalina Mayorga Mayorga
Backup ContactFrancisca Gómez Pérez
Outcome results
None listed